Search
Dexamethasone Treatment Options
A collection of 1462 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States . Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
613 - 624 of 1462
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Terminated
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, leucovorin, vincristine, procarbazine, dexamethasone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving ritu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/14/2023
Locations: Stanford Cancer Center, Stanford, California +67 locations
Conditions: Lymphoma
Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery
Completed
This research will evaluate the efficacy of Omidria and Dexycu, Omidria and Dextenza, and Omidria and prednisolone acetate 1% in the resolution of post-operative inflammation and pain following cataract surgery.
Gender:
ALL
Ages:
All
Trial Updated:
06/13/2023
Locations: Silverstein Eye Centers, Kansas City, Missouri
Conditions: Cataract Surgery
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Completed
The primary objective of the study is to determine the maximum tolerated dose (MTD) of CEP-18770 in combination with lenalidomide and dexamethasone in participants with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2023
Locations: Teva Investigational Site 1, Augusta, Georgia +7 locations
Conditions: Multiple Myeloma
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/05/2023
Locations: Southern Cancer Center, Mobile, Alabama +320 locations
Conditions: Multiple Myeloma
BiRd vs. Rd as Initial Therapy in Multiple Myeloma
Terminated
This is a randomized, open-label, phase III study to investigate the efficacy of combination therapy with an induction phase utilizing a combination clarithromycin (Biaxin®), lenalidomide (Revlimid®), dexamethasone (Decadron®), in multiple myeloma patients who are newly diagnosed and require treatment when compared to patients who receive lenalidomide and dexamethasone alone.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/02/2023
Locations: University of Colorado - Anschutz Cancer Center, Aurora, Colorado +1 locations
Conditions: Multiple Myeloma
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
Completed
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.
- Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/17/2023
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Smoldering Multiple Myeloma
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Completed
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +8 locations
Conditions: Smoldering Myeloma, Smoldering Multiple Myeloma
First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Terminated
This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2023
Locations: Colorado Blood Cancer Institute, Denver, Colorado +4 locations
Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography
Active Not Recruiting
This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography , use a small amount of radioactive substance to show changes in tumor cells. Studying the effects of dexamethasone on lung tumors using FLT positron emission tomography may help doctor... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/04/2023
Locations: Wayne State University/Karmanos Cancer Institute, Detroit, Michigan
Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer
Completed
The purpose of this study was to assess the efficacy and safety of first-line treatment with everolimus plus letrozole in postmenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer.
Moreover, the study also aimed to investigate the efficacy and safety of second line treatment with everolumus plus examestane in participants whose disease progressed during everolimus plus letrozole therapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/28/2023
Locations: University of Alabama Comprehensive Cancer Center SC-2, Birmingham, Alabama +51 locations
Conditions: Hormone Receptor Positive Breast Cancer
Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients
Terminated
Methadone has several advantages over standard narcotic medications, especially when considering use after a typically painful surgery such as lumbar fusion. Methadone is low cost, has a long half-life, has a convenient dosing schedule, has excellent oral bioavailability, and demonstrates slow onset to withdrawal. The literature comparing methadone to more commonly used post-operative narcotics demonstrates that it manages pain better, sustains consistent plasma concentrations, decreases overall... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2023
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Pain, Postoperative
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
Completed
The goal of this clinical research study is to find the highest tolerable dose of paclitaxel that can be given as hyperthermic intraperitoneal chemotherapy (HIPEC) to patients with gastric or gastroesophageal cancer. HIPEC is a system in which heated chemotherapy is delivered directly inside the abdomen during surgery. In this study, paclitaxel is being combined with mitomycin and cisplatin to see if this study drug combination can help to control the disease.
This is an investigational study.... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/20/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Diseases of Oesophagus Stomach and Duodenum
613 - 624 of 1462